Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033810 | 0.80 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL181909 | 0.80 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL65492 | 0.80 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1863662 | 0.78 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL2707862 | 0.78 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL25408690 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL31250397 | 0.78 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| SCHEMBL1863664 | 0.78 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| Ammonia Solution, Strong SCHEMBL19410295 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL31485474 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43676-E1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-7468443-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-23 | — | — | US | disclosed |
| EP-1437353-B1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-7087594-B2 | central nervous system disorders; regenerating nervous systems | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194781-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | SLC6A4 3250/4885SLC6A2 3027/4885SLC6A3 2219/4885 |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | SLC6A4 3250/4885SLC6A2 3027/4885SLC6A3 2219/4885 |
| US-20050070521-A1 | Alkyl ether derivatives or salts thereof | AHNAK, NGF, PMP22 | SLC6A4 3250/4885SLC6A2 3027/4885SLC6A3 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.